|
| |
- Adam C, Dean HJ, Isracls SJ, Patton A, Fewer DH: Primary hypothyroidism
with intracranial hypertension and pituitary hyperplasia. Pediatr Neurol,
1994, 10:166-168.
- Ali SF, Peck Jr. EJ: Modulation of anterior pituitary dopamine receptors
by estradiol 17-13: Dose-response relationship. J Neurosci Res, 1985, 13:497-507.
- Bevan JS, Webster J, Burke CW, Scanlon MF: Dopamine agonists and pituitary
tumor shrinkage. Endocr Rev, 1992, 123:220-240.
- Brawer JR, Naftolin F, Martin J, et al.: Effects of a single injection
of estradiol valerate on the hypothalamic arcuate nucleus and on reproductive
function in the females rat. Endocrinology, 1978, 103:501-511.
- Bression D, Brandi AM, Le Dafniet M, Cesselin F, Hamon M, Martinet M,
Kerdelhue B, Peillon F: Modification of the high and low affinity domperidone-binding
sites in chronic estrogenized rats. Endocrinology, 1983, 113:1799-1805.
- Caron MG, Beaulieu M, Raymond V, Gagne B, Drouin J, Leikowitz RJ, Labrie
F: Dopaminergic receptors in the anterior pituitary gland. Correlation
of 3H-dihydroergocryptine binding with the dopaminergic control ofprolactine
release. J Biol Chem, 1978, 253:2244-2253.
- Casanueva F, Cochi D, Locatelli V, Flauto C, Zambotti F, Bestetti G,
Rossi GL, Muller E: Defective central nervous system dopaminergic function
in rats with estrogen-induced pituitary tumors, as assessed by plasma prolactin
concentrations. Endocrinology, 1982, 110:590-599.
- Croissandeau G, Grouselle D, Li Y, Roche M, Peilon F, Le Defniet M:
Hypothyroidism increases TRH and TRH precursor levels in rat anterioc pituitary.
Biochem Biophys Res Commun, 1994, 201: 12481254.
- Demarest K, Riegle G, Moore K: Long-term tceatment with estradiol induces
reversible alterations in tuberoinfundibular dopaminergic neurons: a decreased
responsiveness to prolactin. Neuroendocrinology, 1984, 39:193-200.
- Di Paolo T, Daigle M, Barden N: Decreased tuberoinfundibular and pituitary
dopamine and dihydroxyphenylacetic acid concentrations in rats with estrogen-induced
pituitary tumors. Neurosci Lett, 1985, 54:251-256.
- Dušková J, Schreiber V: Nucleolar inhibition after combined thyroid
hormone plus lisuride treatment in estrogenized rats. Endocr Exp, 1989,
23:185-195.
- Elias KA, Weiner RI: Inhibition of estrogen-induced anterior pituitary
enlargement and arteriogenesis by bromocriptine in Fischer 344 rats. Endocrinology,
1987, 120:617-621.
- Foord SM, Peters JR, Dieguez C, et al.: Hypothyroid pituitary cells
in culture: An analysis of thyrotropin and prolactin response to dopamine
(DA) and DA receptor binding. Endocrinology, 1984, 115:407-415.
- Friedman E, Adams EF, Hoog A, Gejman PV, Carson E, Larsson C, De Marco
L, Werner S, Fahlbusch R, Nordenskjold M: Normal structural dopamine type
2 receptor gene in prolactin-secreting and other pituitary tumors. J Clin
Endocrinol Metab, 1994, 78:568-574.
- Fuxe K, Hokfelt T: Catecholamines in the hypothalamus and pituitary
gland. In: Ganong WF, Martini L (Eds.): Frontiers in neuroendoccinology.
Oxford, University Press 1969, 47-96.
- Gibbs DM, Neill JD: Dopamine levels in hypophysial stalk in the rat
are sufficient to inhibit prolactin secretion in vivo. Endocrinology, 1978,
102:1895-1900.
- Gottschall PE, Meites MJ: Evidence for a permanent Lecline in tuberoinfundibulac
dopaminergic neuronal function after chronic estrogen treatment is terminated
in Fischer 344 rats. Neuroendocrinology, 1986, 44:211-216.
- Hall TR, Harvey S, Chadwick A: Neurotransmitter effects on in vitro
prolactin and growth hormone release from fowl pituitary glands: dopamione
and noradrenaline. Gen Pharmacol, 1984:321-325.
- Hordon LD, Wright V: Endocrine disorders Curr Opin Rheumatol. 1994,
6:95-102.
- Hruška RE, Nowak MW: Estrogen treatment increases the desnity of D1
dopamine receptors in the rat striatum. Brain Res, 1988, 442: 349-350.
- Inoue A, Yanagisawa M, Imura S, Kasuya Y, et al.: The human endothelin
family: three structurally and pharmacologically distincisopeptides predicted
by three separate genes. Proc Natl Acad Sci USA, 1989, 86:2863-2867.
- Ishibashi M, Yamaji T: Direct effects of catecholamines, thyrotropin-releasing
hormone and somatostatin on growth hormone and prolactin secretion from
adenomatous and nonadenomatous human pituitary cells in culture. J Clin
Invest, 1984, 73:66-78.
- Kalberman LE, Machiavelli G, Di Nicola AF, Weisenberg L, Burdman JA:
Synthesis of DNA in estrogen-induced pituitary tumors: Effects of bromocriptine.
J Endocrinol 1980, 7:221-224.
- Kanyicska B, Livingstone JD, Freeman ME: Long term exposure to dopamine
reverses the inhibitory effect of endothelin-1 on prolactin secretion.
Endocrinology, 1995, 136:990-994.
- Koga M, Nakao H, Sato B: Effects of retinoic acid on estrogen- and thyroid
hormone-induced growth in a newly etablished rat pituitary tumor cell line.
J Steroid Biochem Mol Biol, 1992, 43: 263-270.
- Lamberts SWJ and Macleod RM: Regulation of prolactin secretion at the
level of the lactotroph. Physiol Rev, 1990, 70:279-318.
- Levesque D, Di Paolo T: Dopamine receptor reappearance after irreversible
receptor blockade: effect of chronic estradiol treatment of ovarectomized
rats. Mol Pharmacol, 1991, 39:659-665.
- Lin C, Lin S-C, Chang C-P, Rosenfeld MG (1992): Pit-1-dependent expression
of the receptor for growth hormone celeasing factor mediates pituitary
cell growth. Nature, 360:765-768.
- van Loon GR: A defect in catecholamine neurons in patients with prolactin-secreting
pituitary adenoma. Lancet, 1978, 2:868-871.
- MacLeod RM, Lehmeyer JE: Restoration of prolactin synthesis and release
by the administration of monoaminergic blocking agents to pituitary tumor-bearing
rats. Cancer Res, 1974, 34:345-350.
- MacLeod RM, Lehmeyer JE: Studies on the mechanism of the dopamine-mediated
inhibition of prolactin secretion. Endocrinology, 1974, 94:1077-1085.
- Munemura M, Aquie T, Sibley DR: Chronic estrogen treatment promotes
a functional uncoupling of the D2 dopamine receptor in rat anterior pituitary
gland. Endocrinology, 1989, 124:346-355.
- Murdoch GH, Rosenfeld MG, Evans RM: Eukaryotic transcriptional regulation
and chromatin-associated protein phosphorylation by cyclic AMP. Science,
1982, 333:129-134.
- Müller E, Locatelli V, Cella S, Penalva A, Novelli A, Cocchi D:
Prolactin-lowering and -releasing drugs. Mechanisms of action and therapeutic
applications. Drugs, 1983, 25:399-432.
- Nakahara T, Uchimura H, Hirano M, Saito M, Kim JS, Matsumoto T: Effects
of gonadectomy and thyroidectomy on tyrosine hydroxylase in discrete areas
of the rat median eminence. Brain Res, 1979, 179:396-400.
- Nedvídková J, Schreiber V: The increase in cAMP and cGMP
levels in the oestrogenized rat hypophysis. Physiol Res, 1992, 41: 279-284.
- Nedvídková J, Kasafírek E, Nedvídek J, Pacák
K, Schreiber V: An analog of MIF, Alaptide: Effect on serum prolactin,
dopamine receptors and growth of rat adeoohypophysis. Endocrine Res, 1994,
20:39-46.
- Nedvídková J, Šterzl I, Haluzík M, Schreiber V:
An increase in the blood thyroxine level after methylene blue in rats:
the interaction with carbimazole. Endocrine Res, 1995, 21:709-717.
- Nedvídková J, Pacák K, Nedvídek J, Schreiber,
V: Modulation of rat anterior pituitary dopamine receptors by estradiol
and triiodothyronine. Brain Res, 1995, 21:709-717.
- Pacák K, Nedvídková J, Štolba P, Schreiber V: Estradiol
-induced adenohypophyseal growth reaction and beta-adrenergic receptors.
Physiol Res, 1991, 40:419-425.
- Pacák K, Nedvídková J: Úloha centrálních
katecholaminu a dopaminergních receptoru pri vzniku estrogeny indukované
hypertrofie adenohypofýzy. Cas Lék ces, 1994, 134:296-301.
- Palkovits M, Záborsky L, Feminger A, et al.: Noradrenergic innervation
of the rat hypothalamus: Experimental biochemical and electron microscopic
studies. Brain Res, 1980, 191:161-171.
- Reymond MJ, Benotto W, Lemarchand-Beraud T: The secretory activity of
the tuberoinfundibular dopaminergic neurons is modulated by the thyroid
status in the adult rat: consequence on prolactin secretion. Neuroendocrinology,
1987, 46:62-68.
- Rondeel JMM, de Greef WJ, van der Schoot, Karels B: Effect of thyroid
status and paraventricular area lesions on the release of thyrotropin-releasing
hormone and catecholamines into hypophysial portal blood. Endocrinology,
1988, 123:523-527.
- Ruvkin G: A molecular growth industry. Nature, 1992, 360:711712.
- Sarkar DK, Gottschall PE, Meites J: Decline of tuberoinfundibular dopaminergic
function resulting from chronic hyperprolactinemia in rats. Endocrinology,
1984, 115:1269-1274.
- Selye H, Collip JB, Thomson DL: Effect of oestrin on ovaries and adrenals.
Proc Soc Exp Biol New York, 1935, 32:1377.
- Schreiber V, Pribyl, Rohácová J: Hypertrofie adenohypophysy
po estrogenech. Ces Fysiol, 1970, 19275-277.
- Schreiber V: Dopaminergic control of adenohypophyseal growth. Vopr biochim
Mozg (Yerevan), 1979, 13:221-225.
- Schussler N, Bayet MCh, Frain O, et al.: Evidence of tyrosine hydroxylase
mRNA in the anterior and neurointermediate lobes of female rat pituitary.
Biochem Biophys Res Commun 1992, 189:1716-1724.
- Sibley DR, De Lean A, Creese I: Anterior pituitary dopamine receptors
demonstration of interconvertible high and low affinity states of the DA-2
dopamine receptor. J Biol Chem, 1982, 257:6351-6359.
- Tang TK, Wang SW, Wang PS: Effects of thyroidectomy and thyroxine replacement
on the responsiveness of the anterior pituitaries from male rats to thyrotropin-releasing
hormone in vitro. Experientia, 1986, 42:1031-1034.
- Terry LC, Craig R, Hughes T, et al.: Hypothalamic monoaminergic activity
and pituitary function in male rat with estrogen-induced pituitary hyperplasia.
Neuroendocrinology, 1988, 41:523-527.
- Tuomisto J, Manisto P: Neurotransmitter regulation of anterior pituitary
hormones. Pharmacolog Rev 1985, 37251-300.
- Velardo A, Toschi E, Pantaleoni M, Coletta F, Menozzi R, Marrama P:
Hyperprolactinemia in hypothyroidism: effects of L-thyroxine therapy. Minerva-Endocrinol,
1994, 19:1-4.
- Wang PS, Huang SW, Tung YF, Pu H-F, et al.: Interrelationship between
thyroxine and estradiol on the secretion of thyrotropinreleasing hormone
and dopamine into hypophysial portal blood in ovariectomized-thyroidectomized
rats Neuroendocrinology, 1994, 59:202-207.
- Woods WF, Johnston JM, Johnston DG: Dopamine, the dopamine D2 receptor
and pituitary tumours Clin Endocrinol, 1991, 35:455466.
- Yanagisawa M, Kurihara H, Kimura S, et al.: A novel potent vasoconstrictoc
peptide produced by vascular endothelial cell, 1988, 332: 41l-415.
- Yang JY, Pan JT: Enhanced tuberoinfundibular dopaminergic neuron activity
in thyroidectomized, ovariectomized and estrogen-treated rats with hypecprolactinemia.
Neuroendocrinology, 1994, 59:520-527.
- Zhou-Li F, Joly-Pharaboz MO, Bouillard B, et al.: Multihormonal control
of cell proliferation: Oposite effects of two stimulators (17a- estradiol
and L-triiodothyronine) and one inhibitor (dexamethasone) on F4Z2 pituitary
tumor cells. Endocrinology, 1991, 128:2761-2768.
- Zofková I, Nedvídková J: Effect of 1,25-Dihydroxyvitamin
D2 (Calcitriol) on prolactin secretion at rest and TRH-stimulated secretion
in humans. J Clin Endocrinol, 1988, 91:207-211.
|
|